Mizuho on Terns Pharmaceuticals (TERN): MRK acquisition 'makes sense on multiple levels'
Tweet Send to a Friend
Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $54.00 price target on Terns Pharmaceuticals (NASDAQ: TERN)The analyst commented, "This ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
